Julius-Maximilians-University of Würzburg's cancer immunotherapy developer Catalym plans to move its lead asset into the clinic next month.

Catalym, a Germany-based cancer immunotherapy spinout of Julius-Maximilians-University of Würzburg, completed a €50m ($59m) series B round led by life sciences fund Vesalius Biocapital III yesterday.
The round included Novartis Venture Fund, the strategic investment unit of pharmaceutical firm Novartis, German government-backed investment fund Coparion, Bavarian state-owned Bayern Kapital’s Wachstumsfonds Bayern and venture capital firms BioGeneration Ventures (BGV) and Forbion Capital Partners.
Founded in 2016, Catalym is developing monoclonal antibody treatments for cold tumours which help penetrate mechanisms…